Investigators found that a certain targeted therapy “significantly extended overall survival for patients with previously treated metastatic pancreatic cancer and reduced the risk of death by 60% compared with standard chemotherapy.”
The research team found “patients who received the drug daraxonrasib, an investigational, first-in-class oral RAS(ON) multi-selective inhibitor designed to block active RAS signaling — one of the primary drivers of pancreatic cancer — lived a median of 13.2 months compared with 6.7 months for those who received investigator’s choice chemotherapy in the RAS G12 population.” This suggests a possible investigational treatment option for patients with metastatic cancer.
More than 90% of tumors are “driven by alterations in the RAS signaling pathway, particularly mutations in KRAS, a gene that helps regulate cell growth. When mutated, the gene can lock cells into a constant growth state, fueling tumor development. Despite decades of research, RAS proteins have proved notoriously difficult to target with drugs.”
The study to test the drug involved “500 patients with metastatic pancreatic cancer whose disease had already progressed after one previous treatment from 60 clinical sites across six countries.” Patients treated with “daraxonrasib experienced significantly longer disease control. Median progression-free survival was 7.2 months compared with 3.6 months for chemotherapy, effectively doubling the time before cancer progression, in the ITT population.”
